<?xml version="1.0" ?>
<!DOCTYPE book-part-wrapper PUBLIC 
"-//NLM//DTD BITS Book Interchange DTD v1.0 20130520//EN"
 "../BITS-book1.dtd">
<book-part-wrapper 
  dtd-version="1.0"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xi="http://www.w3.org/2001/XInclude"
  xmlns:mml="http://www.w3.org/1998/Math/MathML"
  xmlns:xlink="http://www.w3.org/1999/xlink">

<book-meta>
<book-id>Lapdeb-1</book-id>
<book-id book-id-type="publisher-id">BITS-Test1</book-id>

<book-title-group>
<book-title>BITS DTD Test book</book-title>
<subtitle>(Just a small one for parsing)</subtitle>
<alt-title>Still Just a BITS test</alt-title>
</book-title-group>

<contrib-group>
<contrib  id="Prime-jjb" rid="aff-1">
<name-alternatives>
<name><surname>Jones</surname>
<given-names>John Browning</given-names>
<prefix>The Honorable</prefix><suffix>III</suffix>
</name>
<name  specific-use="Indexing"><surname>Jones</surname>
<given-names>JBB</given-names>
</name>
<name name-style="eastern" xml:lang="ja-Jpan"  specific-use="Honorary">
<surname>flower-characters here</surname>
<given-names>flower-characters here</given-names>
</name>
</name-alternatives>
</contrib>
<contrib>
<name><surname>Jones</surname>
<given-names>John Browning</given-names>
<prefix>The Honorable</prefix><suffix>III</suffix>
</name>
</contrib>
<aff-alternatives  id="aff-1" >
<aff><institution xmlns:xlink="http://www.w3.org/1999/xlink" 
xlink:type="simple">County Jail</institution> down Aberdeen way
</aff>
<aff>
<institution xmlns:xlink="http://www.w3.org/1999/xlink" 
xlink:type="simple">Montgomery County Jail</institution>
<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:type="simple"
 xlink:href="http://www.archiemcphee.com">Archie McPhee</uri>
</aff>
</aff-alternatives>
</contrib-group>

<author-notes>
<p>All is well, dear child!</p>
</author-notes>
<pub-date><year>2004</year></pub-date>
<issn>000-222-444</issn>
<isbn>xxx-1</isbn>
<isbn>1-234 567890-123</isbn>
<publisher>
<publisher-name>Mulberry Technologies, Inc.</publisher-name>
</publisher>
<edition designator="13">Thirteenth</edition>

<pub-history>
<date date-type="manuscript-received">
<day>29</day>
<month>01</month>
<year>1999</year></date>
<event>
<event-desc>43rd printing special gold bindings edition</event-desc>
<date iso-8601-date="20120401">
<day>April Fool's Day</day>
<month>04</month>
<year>2012</year></date>
<notes><p>Published as a giveaway for our 16th birthday
party</p>
</notes>
</event>
</pub-history>

<permissions>
<copyright-statement>Copyright &#x00A9; 2012, Mulberry
Technologies, Inc.</copyright-statement>
<copyright-year content-type="domestic">2012</copyright-year>
<copyright-holder>Mulberry
Technologies, Inc.</copyright-holder>
</permissions>



<kwd-group kwd-group-type="author">
<kwd>DNA analysis</kwd>
<kwd>gene expression</kwd>

<kwd>parallel cloning</kwd>
<kwd>fluid microarray</kwd>
</kwd-group>

<funding-group>
<award-group id="nih-509">
<funding-source country="US">NIH</funding-source>
<award-id>NIH GM61374</award-id>
<principal-award-recipient>Stanford</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group id="nsf-510">
<funding-source country="US">NSF</funding-source>
<award-id>NSF DBI-0317510</award-id>
<principal-award-recipient>Berkeley</principal-award-recipient>
</award-group>
<award-group id="arda-511"  award-type="contract">
<funding-source country="US">ARDA ACQUAINT</funding-source>
<principal-award-recipient>Berkeley</principal-award-recipient>
</award-group>
<award-group id="geneentech-512" award-type="gift">
<funding-source country="US">Genentech Corp.</funding-source>
<principal-award-recipient>Berkeley</principal-award-recipient>
</award-group>
</funding-group>





</book-meta>

<book-part 
  book-part-type="introduction"
  indexed="no" 
  seq="1" 
  xmlns:mml="http://www.w3.org/1998/Math/MathML"
  xmlns:xlink="http://www.w3.org/1999/xlink" >
<book-part-meta>
<book-part-id>Chapter-swsw-1</book-part-id>

<subj-group>
<subject>Large Poodles</subject>
</subj-group>

<title-group>
<label>Chapter 1.</label>
<title>BITS Book Chapter for DTD Testing</title>
<subtitle>(Still a very small one for parsing)</subtitle>
<alt-title>Bits chapter the first alternate title</alt-title>
</title-group>

<contrib-group>
<contrib rid="chap-aff-1">
<name-alternatives>
<name><surname>Jones</surname>
<given-names>John Browning</given-names>
<prefix>The Honorable</prefix><suffix>III</suffix>
</name>
<name  specific-use="Indexing"><surname>Jones</surname>
<given-names>JBB</given-names>
</name>
<name name-style="eastern" xml:lang="ja-Jpan"  specific-use="Honorary">
<surname>flower-characters here</surname>
<given-names>flower-characters here</given-names>
</name>
</name-alternatives>
</contrib>
<contrib>
<name><surname>Jones</surname>
<given-names>John Browning</given-names>
<prefix>The Honorable</prefix><suffix>III</suffix>
</name>
</contrib>
<aff-alternatives  id="chap-aff-1" >
<aff><institution xmlns:xlink="http://www.w3.org/1999/xlink" 
xlink:type="simple">County Jail</institution> down Aberdeen way
</aff>
<aff>
<institution xmlns:xlink="http://www.w3.org/1999/xlink" 
xlink:type="simple">Montgomery County Jail</institution>
<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:type="simple"
 xlink:href="http://www.archiemcphee.com">Archie McPhee</uri>
</aff>
</aff-alternatives>
</contrib-group>


<author-notes>
<p>All is well, dear child!</p>
</author-notes>
<pub-date><year>2012</year></pub-date>
<issn>000-222-444</issn>
<isbn>xxx-1</isbn>
<isbn>1-234 567890-123</isbn>
<publisher>
<publisher-name>Mulberry Technologies, Inc.</publisher-name>
</publisher>

<pub-history>
<date date-type="manuscript-received">
<day>29</day>
<month>01</month>
<year>1999</year></date>
<event>
<event-desc>43rd printing special gold bindings edition</event-desc>
<date iso-8601-date="20120401">
<day>April Fool's Day</day>
<month>04</month>
<year>2012</year></date>
<notes><p>Published as a giveaway for our 16th birthday
party</p>
</notes>
</event>
</pub-history>

<permissions>
<copyright-statement>Copyright &#x00A9; 2012, Mulberry
Technologies, Inc.</copyright-statement>
<copyright-year content-type="domestic">2012</copyright-year>
<copyright-holder>Mulberry
Technologies, Inc.</copyright-holder>
</permissions>

<abstract><p>All the good stuff</p>
<sec>
<title>Introduction</title>
<p>And not for something completely different</p>
</sec>
<sec>
<title>Discussion</title>
<p>Or maybe not</p>
</sec>
<sec>
<title>Conclusion</title>
<p>All&rsquor;s well that ends well.</p>
</sec>
</abstract>

<kwd-group kwd-group-type="author">
<kwd>DNA analysis</kwd>
<kwd>gene expression</kwd>

<kwd>parallel cloning</kwd>
<kwd>fluid microarray</kwd>
</kwd-group>

<counts>
<fig-count count="5"/>
<table-count count="3"/>
<equation-count count="10"/>
<ref-count count="26"/>
<page-count count="6"/>
<word-count count="2847"/>
</counts>

<notes>
<p>Always more to say</p>
</notes>

</book-part-meta>

<body>
<p>This following is an XHTML table, inside a
Table Wrapper %lt;table-wrap&gt; wrapper, or prehaps
a lettuce leaf, inside an enigma.</p>
<p>Multiple paragrpahs are almost always a good idea
to test 
<list list-type="bullet">
<list-item><p>robustness, and</p></list-item> 
<list-item><p>fortitude.</p></list-item>
</list></p>
<p>The last paragraph had a bulleted list embedded within it,
imagine that! How clever of it.</p>

<!-- =============== An HTML Table =========== -->
<table-wrap id="table-wrap-XHTML" position="anchor">
<label>Table 1</label>
<caption><title>A Titled XHTML Table</title>
<p>Additional caption &rsquo;material, which may spread to one or
more paragraphs</p>
</caption>
<table>
<tbody>
<tr>
<td>A cell!</td>
<td>Another</td>
<td>Still a third&gt;</td>
</tr>
<tr>
<td>2 A cell!</td>
<td>An xref: <xref ref-type="statement" rid="statement16">See the 
statement</xref></td>
<td>2 Still a third&gt;</td>
</tr>
</tbody>
</table>
</table-wrap>
<!-- =============== A Display Formula ======= -->
<disp-formula>
<tex-math id="M1"><![CDATA[\documentclass[12pt]{minimal}
\usepackage{wasysym}
\usepackage[substack]{amsmath}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage[mathscr]{eucal}
\usepackage{mathrsfs}
\DeclareFontFamily{T1}{linotext}{}
\DeclareFontShape{T1}{linotext}{m}{n} { &#x003C;-&#x003E; linotext }{}
\DeclareSymbolFont{linotext}{T1}{linotext}{m}{n}
\DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext}
\begin{document}
$$
{\mathrm{Acc/Acc:\hspace{.5em}}}\frac{{\mathit{ade2-202}}}{{\mathit{ADE2}}}\
hspace{.5em}\frac{{\mathit{ura3-59}}}{{\mathit{ura3-59}}}\hspace{.5em}\frac{{\
mathit{ADE1}}}{{\mathit{adel-201}}}\hspace{.5em}\frac{{\mathit{ter1-Acc}}}{{\
mathit{ter1-Acc}}}\hspace{.5em}\frac{{\mathit{MATa}}}{{\mathit{MAT{\alpha}}}}
$$
\end{document}]]>
</tex-math>
</disp-formula>
<!-- =============== A Section ======= -->
<sec sec-type="methods">
<title>There be statements here.</title>
<statement id="statement11">
<p>The IDREFs need to point to something</p>
</statement>
<statement id="statement15">
<p>No Matter How Wise You Get, Wet Birds Don't 
Fly at Night</p>
</statement>
<statement id="statement16">
<p>Post Hoc Propter Ergo Hoc</p>
<p>EM4 cells, stably transfected with Flag-HA-DAT, Myc-His-DAT,
or both, were reacted with cross-linker and solubilized in Triton X-100
as above. There is no reason to have this formula,<inline-formula>
<mml:math><mml:semantics><mml:mrow><mml:msub><mml:mi>Q</mml:mi>
<mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mo>=
</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow>
<mml:mfrac><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub>
</mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn>
</mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow>
</mml:mrow><mml:mrow><mml:mn>10</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>T
</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>
T</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:msup></mml:mrow>
<mml:annotation>Required: content unknown</mml:annotation>
</mml:semantics></mml:math></inline-formula> here. Five microliters of
anti-Myc 9E10 (Santa Cruz Biotechnology) was added to 1.0 ml of Triton
X-100 extracts, and the mixture was incubated for 1 h at 4&#x00B0;C.
Twenty microliters of rec-protein G Sepharose (Zymed) was added, and the
mixture was incubated for 1 h at 4&#x00B0;C, washed three times in 0.5
ml of lysis buffer, and eluted in 45 &#x03BC;l of 2&#x00D7; Laemmli
sample buffer without reducing agent.</p>

</statement>
</sec>
<sec sec-type="quiz">
<question-wrap content-type="single-select" id="Qw1">
<question id="Q1">
<label>1</label>
<p>The diagnosis of vasculitis rests upon which of the following?</p>
</question>
<answer-set content-type="multiple-choice">
<answer id="Q1-A" correct="no" content-type="multiple-choice">
<label>A</label>
<p>A positive ANCA, PR3, or MPO antibody</p>
</answer>
<answer id="Q1-B" correct="no" content-type="multiple-choice">
<label>B</label>
<p>The presence of pulmonary nodules, cavities, and/or infiltrates</p>
</answer>
<answer id="Q1-C" correct="no" content-type="multiple-choice">
<label>C</label>
<p>The presence of glomerulonephritis</p>
</answer>
<answer id="Q1-D" correct="yes" content-type="multiple-choice">
<label>D</label>
<p>The clinician integrating clinical, laboratory, radiographic, and pathologic data and making a determination that the preponderance of the evidence collectively supports a diagnosis of vasculitis</p>
</answer>
<answer id="Q1-E" correct="no" content-type="multiple-choice">
<label>E</label>
<p>Fulfilling the correct number of elements required by specific published vasculitis classification criteria</p>
</answer>
</answer-set>
</question-wrap>
<question-wrap content-type="single-select" id="Qw2">
<question id="Q2">
<label>2</label>
<p>The recent RAVE trial evaluating rituximab for the induction of disease remission in generalized active and severe vasculitis has found that</p>
</question>
<answer-set content-type="multiple-choice">
<answer id="Q2-A" correct="no" content-type="multiple-choice">
<label>A</label>
<p>Rituximab is superior to cyclophosphamide.</p>
</answer>
<answer id="Q2-B" correct="yes" content-type="multiple-choice">
<label>B</label>
<p>Rituximab is not inferior to cyclophosphamide.</p>
</answer>
<answer id="Q2-C" correct="no" content-type="multiple-choice">
<label>C</label>
<p>Rituximab is associated with significantly fewer serious adverse events than cyclophosphamide.</p>
</answer>
<answer id="Q2-D" correct="no" content-type="multiple-choice">
<label>D</label>
<p>Both A and C</p>
</answer>
<answer id="Q2-E" correct="no" content-type="multiple-choice">
<label>E</label>
<p>Both B and C</p>
</answer>
</answer-set>
</question-wrap>
<question-wrap content-type="single-select" id="Qw3">
<question id="Q3">
<label>3</label>
<p>When a patient with known vasculitis presents with new signs or symptoms, the clinician should strongly consider which of the following possibilities in the differential diagnosis?</p>
</question>
<answer-set content-type="multiple-choice">
<answer id="Q3-A" correct="no" content-type="multiple-choice">
<label>A</label>
<p>Infection</p>
</answer>
<answer id="Q3-B" correct="no" content-type="multiple-choice">
<label>B</label>
<p>Thromboembolic disease</p>
</answer>
<answer id="Q3-C" correct="no" content-type="multiple-choice">
<label>C</label>
<p>Drug toxicity</p>
</answer>
<answer id="Q3-D" correct="no" content-type="multiple-choice">
<label>D</label>
<p>Recurrent disease activity/disease flare</p>
</answer>
<answer id="Q3-E" correct="yes" content-type="multiple-choice">
<label>E</label>
<p>All of the above</p>
</answer>
</answer-set>
</question-wrap>
</sec>

</body>
</book-part>
</book-part-wrapper>
